TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02253927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - D2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - D3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - D4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat breakfast
Study: NCT05255185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: domino therapy
Description: The investigators evaluated routine blood test results, C-reactive protein level, the erythrocyte sedimentation rate, and other indicators. X-rays and CT scans of the surgical site were obtained and the Musculoskeletal Tumor Society (MSTS) score was calculated. Treatment involved debridement and lavage of the prosthesis, and systemic and local antibiotics.
Study: NCT02973633

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diffusion Tensor MRI (DTI)
Description: Diffusion Tensor MRI (DTI) measures the diffusion of water in the heart, which allows the orientation of the muscle fibers in the heart to be determined.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diffusion Tensor MRI (DTI)
Description: Diffusion Tensor MRI (DTI) measures the diffusion of water in the heart, which allows the orientation of the muscle fibers in the heart to be determined.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diffusion Tensor MRI (DTI)
Description: Diffusion Tensor MRI (DTI) measures the diffusion of water in the heart, which allows the orientation of the muscle fibers in the heart to be determined.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadolinium DOTA Meglumine
Description: Late Gadolinium enhancement
Study: NCT04474548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound use
Description: Ultrasound will be used to determine location of IUD after insertion.
Study: NCT01894568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Peglispro
Description: Administered SC using a prefilled pen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC using a prefilled pen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Antihyperglycemic Medications (OAMs)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antihyperglycemic Medications (OAMs)
Description: Administered orally
Study: NCT02685475

Intervention type: DRUG
Intervention: Axillary Brachial Plexus Blocks
Description: All patients received ultrasound-guided axillary brachial plexus block (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.

Intervention type: DRUG
Intervention: Axillary Brachial Plexus Blocks
Description: All patients received ultrasound-guided axillary brachial plexus block (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
Study: NCT04743050

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Tests
Description: All participants will have laboratory tests marking: CRP, fasting glucose, lipid profile, total blood count, and additional tests, which will include blood pressure measurements and measurements of body mass and composition on a specialized body composition analyzer (InBody 270). All the mentioned tests will be performed at the time of joining the research program, after 3 months (in the middle of the research program) and after 6 months (at the end of the research program).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Tests
Description: All participants will have laboratory tests marking: CRP, fasting glucose, lipid profile, total blood count, and additional tests, which will include blood pressure measurements and measurements of body mass and composition on a specialized body composition analyzer (InBody 270). All the mentioned tests will be performed at the time of joining the research program, after 3 months (in the middle of the research program) and after 6 months (at the end of the research program).
Study: NCT01780233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 400 µg sublingual spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actiq® 400 µg transmucosally
Description: Actiq® 400 µg is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl citrate injection 100 µg intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone 50 mg
Description: Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse effects (eg, decreased respiration, nausea) often associated with administration of fentanyl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Description: Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse effects (eg, decreased respiration, nausea) often associated with administration of fentanyl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone 50 mg
Description: Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse effects (eg, decreased respiration, nausea) often associated with administration of fentanyl.
Study: NCT03530514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4461
Description: REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4461
Description: REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4461
Description: REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4461
Description: REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4461
Description: REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4461
Description: REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4461
Description: REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4461
Description: REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4461
Description: REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4461
Description: REGN4461
Study: NCT02768181

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrient supplement to pregnant women (PNS)
Description: A lipid-based micronutrient supplement (LNS) is packed in \~10g sachets. Formulation: Vegetable fat (soy), skimmed milk powder, peanuts, vitamin and mineral complex, sugar, stabilizer: fully hydrogenated vegetable fat, and antioxidant : tocopherols. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc.~Dose: 1 sachet/pregnant woman/day starting from the first counseling session (GA \~125∓15 days) continued till birth of baby. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink.
Study: NCT03530514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN4461
Study: NCT02768181

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrienr supplement to children 6m to 2 years
Description: A lipid-based micronutrient supplement (LNS) is packed in \~10g sachets. Formulation: Vegetable fat, skimmed milk powder, peanuts, sugar, vitamin and mineral complex, maltodextrin, and emulsifier: lecithin. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc. Each 20 g of LNS provide ≥4.46g LA (Linoleic Acid) and ≥0.42g ALA (α-Linolenic Acid).~Dose: 2 sachets \~(10+10=20g)/child/day from 5th completed months (181 days) to 24 completed months of child's age. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrienr supplement to children 6m to 2 years
Description: A lipid-based micronutrient supplement (LNS) is packed in \~10g sachets. Formulation: Vegetable fat, skimmed milk powder, peanuts, sugar, vitamin and mineral complex, maltodextrin, and emulsifier: lecithin. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc. Each 20 g of LNS provide ≥4.46g LA (Linoleic Acid) and ≥0.42g ALA (α-Linolenic Acid).~Dose: 2 sachets \~(10+10=20g)/child/day from 5th completed months (181 days) to 24 completed months of child's age. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink.
Study: NCT00473499

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DEBlue vs Cypher vs BMS
Description: BMS vs DES vs DEB+BMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DEBlue vs Cypher vs BMS
Description: BMS vs DES vs DEB+BMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEBlue vs Cypher vs BMS
Description: BMS vs DES vs DEB+BMS
Study: NCT01767220

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strategy 1 - endocardial ablation
Description: VT substrate mapping and VT ablation are done only from endocardial. Therefore the catheters are introduced through the femoral veins/arteries. For mapping and ablation a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strategy 2 - endocardial and epicardial ablation
Description: VT substrate mapping and VT ablation are done from endocardial and epicardial. Therefore the catheters are introduced through the femoral veins/arteries and into the pericardial space via a pericardial puncture. After endocardial and epicardial mapping, ablation is done from endocardial. In case of an ineffective endocardial ablation and an epicardial substrate an epicardial ablation is done. For mapping and ablation from endo- and epicardial a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
Study: NCT03530514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN4461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN4461
Study: NCT02912364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine
Description: Healthy adults will be titrated onto Eslicarbazepine Acetate (800mg daily) . After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Healthy adults will be titrated onto Carbamazepine (400 mg bid). After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
Study: NCT02544776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomifene citrate ( clomid 50 mg )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomifene citrate ( clomid 50 mg )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Study: NCT03137979

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMSCs and collagen scaffolds
Description: Patients in this group were given GMSCs and collagen scaffolds.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagen scaffolds
Description: Patients in this group were given collagen scaffolds.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open flap debridement
Description: The patients in this group will only receive the treatment of open flap debridement.
Study: NCT02036515

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ertugliflozin 10 mg
Description: Matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks
Study: NCT02641951

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stellate ganglionic block
Description: Ultrasound guided stellate ganglionic block

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pecs II block
Description: Ultrasound guided Pecs II block
Study: NCT05217823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hand instruments
Study: NCT04095104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Phentermine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Release Topiramate
Description: Topiramate tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Phentermine
Description: Compounded tablet to mimic phentermine 8mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Immediate Release Topiramate
Description: Compounded tablet to mimic immediate release topiramate 25mg tablet
Study: NCT00238420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study: NCT03172741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Marijuana
Description: 1-gram marijuana cigarette smoked once per day for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Marijuana
Description: 1-gram marijuana cigarette smoked once per day for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Marijuana
Description: 1-gram marijuana cigarette smoked once per day for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching 1 gram placebo cigarette smoked once per day for 3 months
Study: NCT00859131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit Antithymocyte globulin
Description: 1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclizumab
Description: 1.0 mg/kg pre-op and 1.0 mg/kg on Day 7
Study: NCT00391014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal Amphotericine B
Description: AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.~If patient required ALO-TPH, the prophylaxis should be followed.
Study: NCT00687661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisphosphonate
Description: 35mg given orally once weekly for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical placebo pill once weekly for 24 months
Study: NCT01119339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS 41004
Description: LAS 41004 dosage 1, once daily
Study: NCT02154750

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long, fixed AV delay
Description: Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short, optimized AV delay
Description: Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled.
Study: NCT04567563

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic conditioning (RIC)
Description: Intervention Group: Patients will self-administer RIC treatment with the LifeCuff device 3 times a week. Treatment will be delivered at the patient's home and compliance will be monitored by the LifeCuff device. Control Group: Patients undergo typical standard of care treatment. Assessment of Ulcer Closure: Ulcers will be assessed as completely closed by the Principal Investigator through clinical judgement and photographic support. Patients that completely heal their ulcer during the healing period will complete the study and no further blood or tissue measurements will be taken
Study: NCT00342355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: 600 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: 600 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: 40 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: 40 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Didanosine
Description: \<60 kg/125 mg twice daily or \>60kg/200 mg twice daily
Study: NCT03871361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept 125 MG/ML Prefilled Syringe
Description: Abatacept 125 MG/ML Prefilled Syringe \[Orencia\] weekly
Study: NCT02704286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Based Osteoarthritis Risk Calculator
Description: The investigators have developed a personalized risk calculator for knee osteoarthritis. This risk calculator uses the Osteoarthritis Policy Model to estimate an individual's risk of developing knee osteoarthritis within their lifetime based on demographic information and risk factors. It shows this information to the user with interactive graphs and compares their risk to the risk of an average American of the same age.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Generic osteoarthritis information
Description: Subjects viewed generic (i.e. not personalized) information about osteoarthritis risk factors
Study: NCT02093494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Initial Specimen Diversion Device (ISDD)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lab standard practice (LSP)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Intravenous Catheters (PIVC)
Study: NCT01038661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-hour IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-hour IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-hour IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-3-hour IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-3-hour IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care (BSC)
Description: Any treatment including palliative radiotherapy for pain relief-but not chemotherapy - that is considered appropriate by the investigator
Study: NCT03282162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin
Description: Each subject will be assigned to intranasal administration of oxytocin (24 IU).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin
Description: Each subject will be assigned to intranasal administration of oxytocin (24 IU).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal placebo
Description: An identical amount of intranasal administration of placebo will be assigned to each subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal placebo
Description: An identical amount of intranasal administration of placebo will be assigned to each subject.
Study: NCT02682784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Nasal spray based on naturally occurring hormone, oxytocin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Nasal spray based on naturally occurring hormone, oxytocin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03476265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation of the Lower Esophageal Sphincter
Description: Laparoscopic implantation of an electrical stimulation device to perform an electrical sphincter augmentation for the treatment of GERD.
Study: NCT02664103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of capecitabine and cyclophosphamide SAR439281
Description: Pharmaceutical form:Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of capecitabine and cyclophosphamide SAR439281
Description: Pharmaceutical form:Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of capecitabine and cyclophosphamide SAR439281
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT02017119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison between Lactulose and Lactulose-Paraffin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison between Lactulose and Lactulose-Paraffin